PRLD
Income statement / Annual
Last year (2024), Prelude Therapeutics Incorporated's total revenue was $7.00 M,
and the percentage change from the previous year is not available.
In 2024, Prelude Therapeutics Incorporated's net income was -$127.17 M.
See Prelude Therapeutics Incorporated,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$7.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$1.77 M
|
$1.17 M
|
$3.04 M
|
$2.24 M
|
$542,000.00
|
$382,000.00
|
$149,000.00
|
| Gross Profit |
$5.23 M
|
-$1.17 M
|
-$3.04 M
|
-$2.24 M
|
-$542,000.00
|
-$382,000.00
|
-$149,000.00
|
| Gross Profit Ratio |
0.75
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$118.00 M
|
$103.39 M
|
$92.89 M
|
$86.78 M
|
$48.18 M
|
$24.28 M
|
$12.62 M
|
| General & Administrative Expenses |
$28.72 M
|
$28.88 M
|
$30.65 M
|
$26.96 M
|
$10.59 M
|
$3.83 M
|
$2.35 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$28.72 M
|
$28.88 M
|
$30.65 M
|
$26.96 M
|
$10.59 M
|
$3.83 M
|
$2.35 M
|
| Other Expenses |
$0.00
|
$0.00
|
$8.10 M
|
$2.04 M
|
$1.83 M
|
$539,000.00
|
$295,000.00
|
| Operating Expenses |
$146.71 M
|
$132.28 M
|
$123.54 M
|
$113.74 M
|
$58.76 M
|
$28.11 M
|
$14.98 M
|
| Cost And Expenses |
$146.71 M
|
$132.28 M
|
$123.54 M
|
$113.74 M
|
$58.76 M
|
$28.11 M
|
$14.98 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$1.17 M
|
$3.04 M
|
$2.24 M
|
$542,000.00
|
$382,000.00
|
$149,000.00
|
| EBITDA |
-$139.71 M |
-$131.11 M |
-$122.22 M |
-$112.82 M |
-$58.22 M |
-$27.73 M |
-$14.83 M |
| EBITDA Ratio |
-19.96
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-19.96
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$12.54 M
|
$10.45 M
|
$8.10 M
|
$2.04 M
|
$1.83 M
|
$539,000.00
|
$295,000.00
|
| Income Before Tax |
-$127.17 M
|
-$121.83 M
|
-$115.44 M
|
-$111.69 M
|
-$56.93 M
|
-$27.57 M
|
-$14.68 M
|
| Income Before Tax Ratio |
-18.17
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$8.10 M
|
-$915,000.00
|
$335,703.00
|
$210,140.00
|
$295,000.00
|
| Net Income |
-$127.17 M
|
-$121.83 M
|
-$107.34 M
|
-$110.78 M
|
-$56.93 M
|
-$27.57 M
|
-$14.68 M
|
| Net Income Ratio |
-18.17
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.68 |
-2.02 |
-2.27 |
-2.33 |
-1.3 |
-0.85 |
-0.46 |
| EPS Diluted |
-1.68 |
-2.02 |
-2.27 |
-2.33 |
-1.3 |
-0.85 |
-0.46 |
| Weighted Average Shares Out |
$75.81 M
|
$60.36 M
|
$47.37 M
|
$47.60 M
|
$43.71 M
|
$32.40 M
|
$32.11 M
|
| Weighted Average Shares Out Diluted |
$75.81 M
|
$60.36 M
|
$47.37 M
|
$47.60 M
|
$43.71 M
|
$32.40 M
|
$32.11 M
|
| Link |
|
|
|
|
|
|
|
